Recent advances in medical and surgical therapy were achieved during the last two decades in the management of Crohn's disease (CD). Anti-tumor necrosis factor (anti-TNF) agents are widely used worldwide. However, a significant proportion of patients still need surgical resections. The impact of previous exposure to these agents on the perioperative and postoperative outcomes is still controversial. In this critical review, we aimed to position the strategy of intentional preoperative use of anti-TNF agents in the management of CD. The indications and contraindications for this strategy are detailed, and despite scarce evidence, the possible advantages and disadvantages of the intentional use of anti-TNF agents before abdominal surgery in CD are discussed.

Citations

Citations to this article as recorded by  

• Clinical guidelines. Crohn’s disease (К50), adults
  Yury A. Shelygin, Vladimir T. Ivashkin, Sergey I. Achkasov, Igor V. Reshetov, Igor V. Maev, Elena A. Belousova, Armen V. Vardanyan, Bella A. Nanaeva, Leila V. Adamyan, Oksana M. Drapkina, Leila S. Namazova-Baranova, Aleksandr Yu. Razumovsky, Amiran Sh. Re
  Koloproktologia.2023; 22(3): 10.     CrossRef
• Surgical Management of Small Bowel Crohn's Disease
  Pramodh Chandrasinghe
  Frontiers in Surgery.2022;[Epub]     CrossRef
• Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review
  Abel Botelho Quaresma, Fernanda da Silva Barbosa Baraúna, Fábio Vieira Teixeira, Rogério Saad-Hossne, Paulo Gustavo Kotze
  Journal of Clinical Medicine.2021; 10(4): 710.     CrossRef
• The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn’s Disease
  Amy L. Lightner, Jon D. Vogel, Joseph C. Carmichael, Deborah S. Keller, Samir A. Shah, Uma Mahadevan, Sunanda V. Kane, Ian M. Paquette, Scott R. Steele, • Daniel L. Feingold
  Diseases of the Colon & Rectum.2020; 63(8): 1028.     CrossRef
• Enterocutaneous fistula in severely active Crohn’s disease: preoperative anti-TNF alpha treatment to limit bowel resection—report of a case
  Peter Wilhelm, Andreas Kirschniak, Jonas Johannink, Sascha Kaufmann, Thomas Klag, Jan Wehkamp, Claudius Falch
  International Journal of Colorectal Disease.2019; 34(2): 369.     CrossRef
• Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries
  Tawnya M Hansen, Laura E Targownik, Ahmer Karimuddin, Yvette Leung
  Inflammatory Bowel Diseases.2019; 25(10): 1613.     CrossRef
• Gestion périopératoire des biothérapies en 2019
  Thibault Martinez, Jean Derely, Astrée Swiech, Gaël de Roquigny, Charlotte Delattre, Frederic Banal, Mehdi Ould-Ahmed, Diane Commandeur
  Anesthésie & Réanimation.2019; 5(4): 274.     CrossRef
• Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives
  Alaa El-Hussuna, Pär Myrelid, Stefan D Holubar, Paulo G Kotze, Graham Mackenzie, Gianluca Pellino, Des Winter, Justin Davies, Ionut Negoi, Perbinder Grewal, Gaetano Gallo, Kapil Sahnan, Ines Rubio-Perez, Daniel Clerc, Nicolas Demartines, James Glasbey, Mi
  Crohn's & Colitis 360.2019;[Epub]     CrossRef
• Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis
  Paulo Gustavo Kotze, Christopher Ma, Nicholas Mckenna, Abdulelah Almutairdi, Gilaad G. Kaplan, Laura E. Raffals, Edward V. Loftus, Remo Panaccione, Amy L. Lightner
  Therapeutic Advances in Gastroenterology.2018;[Epub]     CrossRef
• Emerging Therapies: What Are Promising in the Near Future?
  Geom Seog Seo, Sung Hee Lee
  The Korean Journal of Gastroenterology.2018; 71(2): 81.     CrossRef
• Perioperative Care of Patients with Inflammatory Bowel Disease: Focus on Nutritional Support
  Patrick L. Stoner, Amir Kamel, Fares Ayoub, Sanda Tan, Atif Iqbal, Sarah C. Glover, Ellen M. Zimmermann
  Gastroenterology Research and Practice.2018; 2018: 1.     CrossRef